Serialization Case Study: Aggregation And CMO Integration

Download PDF Attachment

We respect your privacy, by clicking "Download Your Copy" you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object . In addition, you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data click here. You can unsubscribe at any time.

As the pharmaceutical industry prepares itself for serialization, many questions arise in regards to best practices that will ensure product traceability throughout the supply chain and compliance on an international scale. In particular, manufacturers have expressed concern as to how their contract partners are preparing for and planning to hit the 2017 DSCSA deadline and what they can do to help them along. Aside from supply chain partner readiness, the decision to aggregate serialized product prior to 2023 is a top area of interest. We are leaning on the expert opinions of top pharmaceutical professionals for further clarification on these pain points.


Matt Sample, Senior Director, Secure Supply Chain at AmerisourceBergen, discusses aggregation challenges, possible solutions, and hitting DSCSA deadlines. He will elaborate on these ideas and more at this year’s Pharmaceutical Traceability Forum. Christopher Howell, Senior Director, Global Engineering & Technology at Patheon, Inc., shares his views on serialization and CMO integration, including some of the top challenges, possible explanations for increasing supply chain efficiency, and anticipated issues past 2017. Like Matt Sample and other distinguished speakers, he will also be presenting at the Pharmaceutical Traceability Forum.

Have Your Say
Rate this feature and give us your feedback in the comments section below